Arvinas (ARVN) Non-Current Deffered Revenue (2017 - 2026)

Arvinas (ARVN) recorded quarterly Non-Current Deffered Revenue of $138.2 million in Q1 2026, up 2.9% quarter-over-quarter from $134.3 million in Q4 2025, and up 16.72% on a YoY basis from $118.4 million in Q1 2025.

Arvinas (ARVN) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends

Arvinas' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $138.2 million for Q1 2026.

  • In Q1 2026, Non-Current Deffered Revenue rose 16.72% year-over-year to $138.2 million; the TTM figure through Mar 2026 stood at $138.2 million (up 16.72% YoY), while the FY2025 annual figure was $134.3 million, down 54.01% from the prior year.
  • Non-Current Deffered Revenue was $138.2 million for Q1 2026 at Arvinas, up from $134.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $521.9 million in Q1 2022 to a low of $118.4 million in Q1 2025.
  • Historically, Non-Current Deffered Revenue has averaged $304.9 million across 5 years, with a median of $310.5 million in 2023.
  • The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue surged 3221.04% in 2022, then tumbled 67.2% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $405.1 million in 2022, then decreased by 4.67% to $386.2 million in 2023, then retreated by 24.39% to $292.0 million in 2024, then sank by 54.01% to $134.3 million in 2025, then rose by 2.9% to $138.2 million in 2026.
  • The last three Non-Current Deffered Revenue figures came in at $138.2 million (Q1 2026), $134.3 million (Q4 2025), and $127.4 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Arvinas 492.16 Mn -122.74 Mn - 138.20 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 138.20 Mn
Dec 31, 2025 134.30 Mn
Sep 30, 2025 127.40 Mn
Jun 30, 2025 134.10 Mn
Mar 31, 2025 118.40 Mn
Dec 31, 2024 292.00 Mn
Sep 30, 2024 304.50 Mn
Jun 30, 2024 331.30 Mn
Mar 31, 2024 361.00 Mn
Dec 31, 2023 386.20 Mn
Sep 30, 2023 281.90 Mn
Jun 30, 2023 310.50 Mn
Mar 31, 2023 378.90 Mn
Dec 31, 2022 405.10 Mn
Sep 30, 2022 464.60 Mn
Jun 30, 2022 493.60 Mn
Mar 31, 2022 521.90 Mn
Dec 31, 2021 534.30 Mn
Sep 30, 2021 600.43 Mn
Jun 30, 2021 14.86 Mn